Johnson and Johnson 2013 Annual Report Download - page 59

Download and view the complete annual report

Please find page 59 of the 2013 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

Pre-Tax Profit Identifiable Assets
(Dollars in Millions) 2013(3) 2012(4) 2011(5) 2013 2012 2011
Consumer $1,973 1,693 2,096 $23,711 24,131 24,210
Pharmaceutical 9,178 6,075 6,406 23,783 23,219 23,747
Medical Devices and Diagnostics 5,261 7,187 5,263 44,585 42,926 23,609
Total 16,412 14,955 13,765 92,079 90,276 71,566
Less: Expense not allocated to segments(1) 941 1,180 1,404
General corporate(2) 40,604 31,071 42,078
Worldwide total $15,471 13,775 12,361 $132,683 121,347 113,644
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions) 2013 2012 2011 2013 2012 2011
Consumer $533 468 670 $539 575 631
Pharmaceutical 856 737 729 1,075 1,010 958
Medical Devices and Diagnostics 1,724 1,230 1,095 2,224 1,857 1,331
Segments total 3,113 2,435 2,494 3,838 3,442 2,920
General corporate 482 499 399 266 224 238
Worldwide total $3,595 2,934 2,893 $4,104 3,666 3,158
Sales to Customers Long-Lived Assets(6)
(Dollars in Millions) 2013 2012 2011 2013 2012 2011
United States $31,910 29,830 28,908 $35,880 35,115 23,529
Europe 18,599 16,945 17,129 24,868 25,261 19,056
Western Hemisphere excluding U.S. 7,421 7,207 6,418 3,281 3,636 3,517
Asia-Pacific, Africa 13,382 13,242 12,575 2,434 2,362 2,163
Segments total 71,312 67,224 65,030 66,463 66,374 48,265
General corporate 992 899 750
Other non long-lived assets 65,228 54,074 64,629
Worldwide total $71,312 67,224 65,030 $132,683 121,347 113,644
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2013, 2012 and 2011, the Company did not have a customer that represented 10% of total revenues.
(1) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income)
expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in
2012 and 2011, respectively.
(2) General corporate includes cash and marketable securities.
(3) Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and
Diagnostics and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the
Medical Devices and Diagnostics segment. Includes $580 million of in-process research and development expense, comprised of
$514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. The Medical
Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASR™ Hip program.
Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and
Pharmaceutical segments, respectively.
(4) Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical
Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense,
comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively.
Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909
million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical,
Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also
includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
(5) Includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical
Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million
expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical
Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.
(6) Long-lived assets include property, plant and equipment, net for 2013, 2012 and 2011 of $16,710, $16,097 and $14,739,
respectively, and intangible assets and goodwill, net for 2013, 2012 and 2011 of $50,745, $51,176 and $34,276, respectively.
Johnson & Johnson 2013 Annual Report •49